Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sitagliptin

sitagliptin

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sitagliptin

153 trials tracked of sitagliptin: 116 in phase 3 or 4 and 27 with published results. The most-cited published study has 2621 citations.

153Trials tracked
116Phase 3 & 4
0Recruiting
27With published results
Phase distribution
Phase 4 42 Phase 3 74 Phase 2 18 Phase 1 8 Other / NA 11
  1. Phase 3 Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) Completed · 2,621 cited
  2. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Completed · 491 cited
  3. Phase 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Completed · 419 cited
  4. Phase 3 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Completed · 285 cited
  5. Phase 4 Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes Completed · 168 cited
  6. Phase 3 Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) Completed · 156 cited
Show 44 more trials
  1. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes Completed · 126 cited
  2. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Completed · 111 cited
  3. Phase 3 Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Completed · 87 cited
  4. Phase 4 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed · 80 cited
  5. Phase 4 Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure Completed · 58 cited
  6. Phase 3 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Completed · 53 cited
  7. Phase 3 Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) Completed · 45 cited
  8. Phase 4 The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome Completed · 42 cited
  9. Phase 4 Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin Completed · 35 cited
  10. Phase 3 Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) Completed · 32 cited
  11. Phase 4 Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy Completed · 30 cited
  12. Phase 4 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant Completed · 24 cited
  13. Phase 3 A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes Completed · 23 cited
  14. Phase 3 Randomized Sitagliptin Withdrawal Study (MK-0431-845) Completed · 20 cited
  15. Phase 4 A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) Completed · 15 cited
  16. Phase 3 A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848) Completed · 12 cited
  17. Phase 4 Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355) Completed · 11 cited
  18. Phase 4 Effect of DPP4 Inhibition on Growth Hormone Secretion Completed · 9 cited
  19. Phase 3 Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) Completed · 7 cited
  20. Phase 3 Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) Completed · 7 cited
  21. Phase 3 Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) Completed · 4 cited
  22. Phase 4 Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics Completed
  23. Phase 4 Response To Oral Agents in Diabetes (ROAD)- Pilot Study Completed
  24. Phase 4 Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery Completed
  25. Phase 4 Sitagliptin in Non-Diabetic Patients Undergoing General Surgery Completed
  26. Phase 4 Sitagliptin Dose Determination Study Completed
  27. Phase 4 Effect of DPP4 Inhibition on Vasoconstriction Completed
  28. Phase 4 Sitagliptin and Glucagon Counterregulation Completed
  29. Phase 4 Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes Completed
  30. Phase 4 Treatment of Diabetes in Patients With Systolic Heart Failure Completed
  31. Phase 4 Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery Completed
  32. Phase 4 SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients) Completed
  33. Phase 4 Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant Completed
  34. Phase 4 Cardiovascular Effects of GLP-1 Receptor Activation Completed
  35. Phase 4 Anti-Diabetic Medications to Fight PD and LBD Completed
  36. Phase 4 Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158) Completed
  37. Phase 4 The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Completed
  38. Phase 4 Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione Completed
  39. Phase 4 Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes Completed
  40. Phase 4 ALPHA Sitagliptin Add on to Metformin (0431-103) Completed
  41. Phase 4 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) Completed
  42. Phase 4 Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea Completed
  43. Phase 4 Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome Completed
  44. Phase 4 Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM Completed

Showing the 50 most-cited and recently-updated of 153 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Adipo-B correlates with beta-cell indices in treatment-naive patients with Type 2 Diabetes
Diabetes & Endocrinology RCT
Adipo-B correlates with beta-cell indices in treatment-naive patients with Type 2 Diabetes New marker may help track insulin production in Type 2 Diabetes
This prospective, non-randomized observational study of 253 treatment-naive patients with Type 2 Diabetes found that adipo-B levels correlat…
A new protein marker could offer a simple way for doctors to track how well the body produces insulin in people with Type 2 Diabetes.
medRxiv Oct 27, 2026
Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes
Nutrition & Obesity Medicine RCT
Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes Two diabetes drugs outperform others in long-term glucose control
This randomized trial compared adding sitagliptin, liraglutide, glimepiride, or insulin glargine to metformin in 1,080 participants with typ…
A five-year trial shows sitagliptin and liraglutide offer better glucose stability and safety than glimepiride or insulin glargine for peopl…
Diab Care Jun 1, 2026
Oral denatonium acetate (ARD-101) reduced weight versus placebo in adults with obesity over 28 days
Diabetes & Endocrinology RCT
Oral denatonium acetate (ARD-101) reduced weight versus placebo in adults with obesity over 28 days Could a Bitter Pill Trick Your Gut Into Feeling Full?
Randomized, placebo-controlled clinical studies and preclinical mouse studies evaluated oral denatonium acetate (ARD-101) in adults with obe…
A new gut-targeted pill tricks your intestines into feeling full, reducing hunger and helping adults lose weight in early human trials.
Apr 10, 2026